^
Association details:
Biomarker:PIK3CA mutation
Cancer:Thyroid Gland Carcinoma
Drug:MK-2206 (AKT inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

The Akt-Specific Inhibitor MK2206 Selectively Inhibits Thyroid Cancer Cells Harboring Mutations That Can Activate the PI3K/Akt Pathway

Excerpt:
We examined the effects of MK2206 on thyroid cancer cells with respect to the genotypes of the PI3K/Akt pathway....The SW1736 cell, lacking mutations in the PI3K/Akt pathway, had minimal response to MK2206, but transfection with exogenous PIK3CA mutants, PIK3CA H1047R and E545K, significantly increased its sensitivity to MK2206.
DOI:
10.1210/jc.2010-2644